唑来膦酸注射液治疗骨质疏松症的研究进展
作者：李佩芳;宁宁;
Author：
收稿日期： 年卷（期）页码：2016,31(04):-436-438
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：双膦酸盐;密固达;骨质疏松;骨折;治疗
Key words：
基金项目：
中文摘要
双膦酸盐是目前各国指南认可的治疗骨质疏松症的一线药物,唑来膦酸注射液(密固达)作为新一代的双膦酸盐制剂而备受关注。文中综述了密固达治疗骨质疏松症的作用机制、研究现状、临床应用、不良反应及依从性,为其治疗骨质疏松症的临床应用提供依据。
参考文献
[1]刘忠厚.骨质疏松学[M].北京:科学出版社,2001.
[2]周丕琪,沈霖,杨艳萍,等.密固达治疗骨质疏松症患者的临床观察[J].中国中医骨伤科杂志,2011,19(6):36-37.
[3]Russell RG.Bisphosphonates:From bench to bedside[J].Ann NY Acad Sci,2006,1068(1):367-401.
[4]Nancollas GH,Tang R,Phipps RJ,et al.Novel insights into actions of bisphosphonates on bone:differences in interactions with hydroxyapatite[J].Bone,2006:38(5):617-627.
[5]Coxon FP,Helfrich MH,Van’t Hof R,et al.Protein geranylgeranylation is required for osteoclast formation,function,and survival:Inhibition by bis-phosphonates and GGTI-298[J].J Bone Miner Res,2000,15(8):1467-1476.
[6]Gasser JA,Ingold P,Venturiere A,et al.Long-term protective effects of Zoledronic acid on canxellous and cortical bone in the ovariectomized rat[J].J Bone Miner Res,2008,23(4):544-551.
[7]Chen T,Berenson J,Vescio R,et al.Pharmacokinetics and pharmacodynamics of Zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228-1236.
[8]Pietrzik K,Bailey L,Shane B.Folic acid and L-5-methyltetrahydrofolate:Comparison of clinical pharmacokinetics and pharmacodynamics[J].Clin Pharmacokinet,2010,49(8):535-548.
[9]Briot K,Cortet B,Thomas T,et al.2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis[J].Joint Bone Spine,2012,79(3):304-313.
[10]Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
[11]Lyles KW,Colon-Emeric CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture[J].N Engl J Med,2007,357(18):1799-1809.
[12]Rakel A,Boucher A,Ste-Marie LG.Role of Zoledronic acid in the prevention and treatment of osteoporosis[J].Clin Interv Aging,2011,6:88-99.
[13]赵方,丛宝华,宋飞.密固达(Zoledronic)治疗女性绝经后及老年性骨质疏松症疗效分析[J].中国骨质疏松杂志,2011,17(10):915-916.
[14]陆琳松,周文正,孙治国,等.唑来膦酸治疗维吾尔族绝经后妇女骨质疏松症患者的临床观察[J].新疆医科大学学报,2013,36(12):1800-1803.
[15]赵海燕,张晓莉,王晓非.唑来膦酸钠治疗糖皮质激素性骨质疏松症50例临床观察[J].中国实用内科杂志,2010(12):1125.
[16]黄永明,徐逸生,肖春生,等.密固达对骨质疏松患者中短期生存质量的影响[J].中国骨质疏松杂志,2012,18(12):1105-1108.
[17]刘静.密固达注射液治疗45例老年骨质疏松症患者的效果观察[J].中外医疗,2013,32(30):90-92.
[18]赵利民,赵维彪,李毅,等.密固达治疗绝经后骨质疏松症的临床观察[J].航空航天医学杂志,2013,24(06):714-715.
[19]费琦,王炳强,唐海,等.密固达治疗原发性骨质疏松症的临床应用初探[J].中国医药导报,2011,08(13):68-70.
[20]Roelofs AJ,Jauhiainen M,Monkkonen H,et al.Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP[J].Br J Heamatol,2009,144(2):245-250.
[21]张菊,徐霞,赵东宝,等.密固达治疗280例骨质疏松症的安全性分析[J].中国骨质疏松杂志,2014,20(08):940-942.
[22]Woo SB,Hellstein JW,Kalmar JR.Bisphosphonates and osteonecrosis of the jaws[J].Ann Intern Med,2006,144(10):753-761.
[23]Saag K,Lindsay R,Kriegman A,et al.A single Zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal woman with low bone mineral density[J].Bone,2007,40(5):1238-1243.
[24]夏巧红.密固达治疗绝经后妇女骨质疏松症的综合护理[J].当代护士,2014,4:60-62.
【关闭】
